Seegene, Inc. (096530.KQ)
KRW 23550.0
(-1.26%)
KRW 23550.0
(-1.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 221.05 Billion KRW | -8.09% |
| 2022 | 240.49 Billion KRW | -40.78% |
| 2021 | 406.12 Billion KRW | -9.38% |
| 2020 | 448.16 Billion KRW | 944.93% |
| 2019 | 42.88 Billion KRW | 15.1% |
| 2018 | 37.26 Billion KRW | -8.67% |
| 2017 | 40.79 Billion KRW | -39.77% |
| 2016 | 67.74 Billion KRW | 0.82% |
| 2015 | 67.18 Billion KRW | 54.04% |
| 2014 | 43.61 Billion KRW | -2.19% |
| 2013 | 44.59 Billion KRW | 6.99% |
| 2012 | 41.67 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 224.45 Billion KRW | -0.67% |
| 2024 Q1 | 225.96 Billion KRW | 2.22% |
| 2023 Q2 | 216.28 Billion KRW | -11.83% |
| 2023 Q4 | 221.05 Billion KRW | 3.72% |
| 2023 FY | 221.05 Billion KRW | -8.09% |
| 2023 Q1 | 245.3 Billion KRW | 2.0% |
| 2023 Q3 | 213.11 Billion KRW | -1.46% |
| 2022 Q4 | 240.49 Billion KRW | -3.04% |
| 2022 Q3 | 248.03 Billion KRW | -18.83% |
| 2022 Q2 | 305.58 Billion KRW | -31.55% |
| 2022 Q1 | 446.41 Billion KRW | 9.92% |
| 2022 FY | 240.49 Billion KRW | -40.78% |
| 2021 Q1 | 458.06 Billion KRW | 2.21% |
| 2021 Q4 | 406.12 Billion KRW | 20.27% |
| 2021 Q3 | 337.66 Billion KRW | -4.96% |
| 2021 FY | 406.12 Billion KRW | -9.38% |
| 2021 Q2 | 355.28 Billion KRW | -22.44% |
| 2020 Q3 | 338.6 Billion KRW | 77.93% |
| 2020 FY | 448.16 Billion KRW | 944.93% |
| 2020 Q1 | 81.18 Billion KRW | 89.29% |
| 2020 Q2 | 190.3 Billion KRW | 134.4% |
| 2020 Q4 | 448.16 Billion KRW | 32.36% |
| 2019 Q1 | 32.35 Billion KRW | -8.73% |
| 2019 FY | 42.88 Billion KRW | 15.1% |
| 2019 Q3 | 35.6 Billion KRW | -14.44% |
| 2019 Q2 | 41.61 Billion KRW | 28.63% |
| 2019 Q4 | 42.88 Billion KRW | 20.45% |
| 2018 Q3 | 27.69 Billion KRW | -12.72% |
| 2018 Q2 | 31.73 Billion KRW | 0.49% |
| 2018 Q1 | 31.57 Billion KRW | -20.04% |
| 2018 FY | 37.26 Billion KRW | -8.67% |
| 2018 Q4 | 35.44 Billion KRW | 27.99% |
| 2017 Q4 | 39.49 Billion KRW | -12.03% |
| 2017 Q2 | 71.16 Billion KRW | 4.69% |
| 2017 FY | 40.79 Billion KRW | -39.77% |
| 2017 Q1 | 67.97 Billion KRW | 3.96% |
| 2017 Q3 | 44.89 Billion KRW | -36.91% |
| 2016 FY | 67.74 Billion KRW | 0.82% |
| 2016 Q3 | 61.97 Billion KRW | -0.33% |
| 2016 Q1 | 59.63 Billion KRW | 1.52% |
| 2016 Q2 | 62.17 Billion KRW | 4.26% |
| 2016 Q4 | 65.38 Billion KRW | 5.51% |
| 2015 Q2 | 35.8 Billion KRW | -26.84% |
| 2015 FY | 67.18 Billion KRW | 54.04% |
| 2015 Q4 | 58.74 Billion KRW | 0.53% |
| 2015 Q3 | 58.43 Billion KRW | 63.19% |
| 2015 Q1 | 48.94 Billion KRW | 12.21% |
| 2014 Q4 | 43.61 Billion KRW | -6.83% |
| 2014 Q3 | 46.81 Billion KRW | 1.26% |
| 2014 Q2 | 46.23 Billion KRW | 6.07% |
| 2014 Q1 | 43.58 Billion KRW | -2.26% |
| 2014 FY | 43.61 Billion KRW | -2.19% |
| 2013 FY | 44.59 Billion KRW | 6.99% |
| 2013 Q3 | 36.53 Billion KRW | -1.38% |
| 2013 Q4 | 44.59 Billion KRW | 22.06% |
| 2013 Q1 | 44.87 Billion KRW | 7.67% |
| 2013 Q2 | 37.04 Billion KRW | -17.44% |
| 2012 FY | 41.67 Billion KRW | 0.0% |
| 2012 Q4 | 41.67 Billion KRW | 3.44% |
| 2012 Q3 | 40.29 Billion KRW | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 27.25 Billion KRW | -711.024% |
| InBody Co.,Ltd | 24.62 Billion KRW | -797.813% |
| Curexo Inc. | 6.94 Billion KRW | -3084.718% |
| i-SENS, Inc. | 195.32 Billion KRW | -13.174% |
| Ray Co., Ltd. | 128.35 Billion KRW | -72.218% |
| Gencurix Inc. | 21.49 Billion KRW | -928.22% |
| Sugentech Inc. | 20.73 Billion KRW | -966.232% |
| L&C Bio Co., Ltd | 105.37 Billion KRW | -109.778% |